Retrieved on:
Wednesday, April 24, 2024
Heart,
Blood,
European Patent Convention,
Hypertrophy,
ECG,
HSCS,
Intelligence,
Environment,
Patent,
Patient,
Death,
Cardiovascular disease,
Growth,
Medical device Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.
Key Points:
- Diastolic dysfunction (impaired cardiac relaxation) is a sensitive and crucial indicator of overall heart health, providing one of the earliest signs of heart disease, with onset typically occurring before symptoms.
- Diastolic dysfunction is caused by all common issues that affect heart function or that produce hypertrophy.
- Today, measures of diastolic function of the heart need to be assessed in a specialist cardiology environment, typically using echocardiography-based imaging.
- The United States Patent and Trademark Office has issued eight utility patents and one design patent to HeartSciences, with patent expiration dates ranging from March 2031 through August 2040.
Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.
Key Points:
- Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.
- Mr. Simpson will also be hosting one-on-one meetings through the conference.
Diabetes,
Disease,
Echocardiography,
HSCS,
Congress,
Algorithm,
Intelligence,
Anesthesia,
Patient,
Mortality,
LVDD,
Society,
Anesthesiology,
Type,
Use,
American Society of Echocardiography,
Medical device Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
Key Points:
- Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
- In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
- For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
- Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.
Diabetes,
Health,
HSCS,
Algorithm,
Intelligence,
Patient,
Acquisition,
Death,
Cardiology,
Completeness,
Patent,
Cardiovascular disease,
FDA,
Regulation,
Police,
Medical device Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
Key Points:
- Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
- HeartSciences has seen a fundamental change in its business opportunity since the end of the second fiscal quarter, with material improvements to its financial position and outlook.
- During the third quarter fiscal 2024, the Company raised $9.2 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
- Complete financial results have been filed in the Company’s quarterly report on Form 10-Q with Securities Exchange Commission and is available on the Company’s website.
Diabetes,
ARIC,
HSCS,
Cardiovascular disease,
Algorithm,
Learning,
Risk,
Intelligence,
Patient,
Atherosclerosis,
HF,
Death,
Type 2 diabetes,
Type,
Use,
T2DM,
Cardiovascular Diabetology,
Medicine,
Medical device Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
Key Points:
- Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
- Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista® wavECG™ features was superior to NT-proBNP, as well as a conventional screening tool—the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.
- This independent study provides evidence of the clinical and diagnostic capabilities of AI-ECG, and specifically our MyoVista wavECG technology, to potentially advance current standards of care for heart screening in diabetic patients.” said Andrew Simpson, Chief Executive Officer of HeartSciences.
- “Globally cardiovascular disease accounts for approximately one-third of all annual deaths and AI-ECG is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, not only for diabetic patients, but also for a significant number of at-risk patients.
Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No.
Key Points:
- Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No.
- 3,000,369 has been granted by the Canadian Intellectual Property Office.
- Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of conventional ECG’s are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs.
- We are pleased to receive this latest patent grant in Canada.
Retrieved on:
Monday, February 26, 2024
Sengupta,
HSCS,
Rutgers University,
Division,
AI,
Intelligence,
Cardiac imaging,
Education,
Teaching,
Echocardiography,
University School,
Editor-in-chief,
ECG,
American Medical Association,
Society,
Heart failure,
Lung,
TEDMED,
European Society of Cardiology,
Journal,
FACC,
MBBS,
Publication,
Holography,
Research,
Medical device Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
Key Points:
- Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
- He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
- In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
- I look forward to helping HeartSciences further advance the field of AI in cardiology.”
Retrieved on:
Monday, February 12, 2024
Bangladesh Technical Education Board,
Accreditation,
HSCS,
American Society of Echocardiography,
Algorithm,
Research,
American Heart Association,
Artificial intelligence,
AI,
Intelligence,
Assistant,
FDA,
Outcomes research,
Diagnostic medical sonography,
ECG,
Education,
Society,
GE HealthCare,
American College,
Journal,
Machine learning,
Harvard Medical School,
ACC,
Commission,
Medical device Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
Key Points:
- Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
- Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medicine at Mount Sinai, New York.
- Dr. Strom has expertise in AI-based medical devices and is a consultant to GE Healthcare, Phillips Healthcare, and Edwards Life Sciences.
- HeartSciences is an innovator in this field, and I look forward to helping them unleash the potential power of AI-powered ECGs to help clinicians deliver timely and optimal care.
Retrieved on:
Thursday, February 1, 2024
Intelligence,
Genetics,
University,
Cardiovascular disease,
Machine learning,
Diagnosis,
FDA,
Drug discovery,
ECG,
Doctor of Philosophy,
Health,
HSCS,
Assistant,
Patent,
Algorithm,
Data science,
Medical device Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
Key Points:
- Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
- “We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences’ Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
- As part of this process, we are actively expanding our Scientific Advisory Board to include industry experts and broaden our outreach.
- I am impressed by their proven track record of innovation and look forward to contributing to HeartSciences at the forefront of this field.”
Retrieved on:
Thursday, January 18, 2024
Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
Key Points:
- Southlake, TX, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today the results of the Company’s 2024 Annual Meeting of Shareholders (the “Annual Meeting”) as well as an adjournment of the Annual Meeting as outlined below.
- At the Annual Meeting which was convened, all items of business were passed, with the exception of Proposal 7, which would effect a reduction of the quorum requirements for future shareholder meetings, as the Company had not received sufficient proxies for approval by the time of the Annual Meeting.
- Each director nominee received a plurality of votes cast at the Annual Meeting.
- The Annual Meeting, with respect to Proposal 7, will reconvene on Thursday, February 15, 2024 at 9:00 a.m. Eastern Time.
